The three top hits, ranked by percentage of tumors contributing to the CIS, were Raf1 (alias C-Raf), Bach2 and Fli1. Over 25% of all tumors had a mutation in one of these three genes, and half of these tumors had mutations in at least two of the genes. Here, BACH2 is linked to in situ carcinoma.